<DOC>
	<DOC>NCT02640157</DOC>
	<brief_summary>The purpose of this study is to compare the safety and efficacy of ABT-493/ABT-530 to the combination of Sofosbuvir (SOF) and Daclatasvir (DCV) in adults with genotype 3 chronic hepatitis C virus (HCV) infection.</brief_summary>
	<brief_title>A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Screening laboratory result indicating HCV GT3 infection Chronic HCV infection Subject must be treatmentna√Øve Subjects must be noncirrhotic History of severe, lifethreatening or other significant sensitivity to any excipients of the study drugs. Female who is pregnant, planning to become pregnant during the study, or breastfeeding; or male whose partner is pregnant or planning to become pregnant during the study. Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol in the opinion of the investigator. Positive test result at Screening for hepatitis B surface antigen (HBsAg) or antihuman immunodeficiency virus antibody (HIV Ab). HCV genotype performed during screening indicating coinfection with more than one HCV genotype.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>interferon free</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>daclatasvir</keyword>
	<keyword>Sovaldi</keyword>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>Hepatitis C Genotype 3</keyword>
	<keyword>Hep C</keyword>
	<keyword>sofosbuvir</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Daklinza</keyword>
</DOC>